Cinta Hierro
YOU?
Author Swipe
View article: Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis
Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis Open
Cure is an informative endpoint in localised oesophageal cancer. In this registry analysis, perioperative FLOT was associated with higher cure rates than CROSS, particularly in high-risk subgroups. Exploratory findings suggest that alterna…
View article: KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials
KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials Open
KRAS mutations occur in over one-third of colorectal cancers (CRC), primarily affecting codons 12 and 13, and less frequently codons 61, 117, and 146. Rare mutations in other codons have been reported, but often lack clear functional signi…
View article: Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914) Open
Purpose: Multikinase inhibitors have shown efficacy in endocrine neoplasms, and synergism with immune checkpoint inhibitors has been noted in other tumors. Patients and Methods: This is a prospective, multicenter, open-label, Simon two-sta…
View article: Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study
Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study Open
In asymptomatic mEGC, immediate start of treatment is preferred by European experts. Consensus was established that treatment can be deferred for patients who prefer deferral and either have a pre-existent WHO/ECOG performance status of 2 …
View article: A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors Open
Background: Bimiralisib is a pan-PI3K/mTOR inhibitor demonstrating antitumor efficacy in preclinical models. The objectives of this study were to identify a maximum tolerated dose (MTD), pharmacokinetics (PK), a dosing schedule, and advers…
View article: Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry Open
Background The optimal chemotherapy backbone for HER2-negative advanced esophagogastric cancer, either in combination with targeted therapies or as a comparator in clinical trials, is uncertain. The subtle yet crucial differences in platin…
View article: 67P Inflammation status and sarcopenia synergistically impact outcomes in cancer patients (pt) treated with ImmunOtherapy (IO) within the framework of a Molecular Pre-screening program (MP) and a spEcial Medication (ME) program
67P Inflammation status and sarcopenia synergistically impact outcomes in cancer patients (pt) treated with ImmunOtherapy (IO) within the framework of a Molecular Pre-screening program (MP) and a spEcial Medication (ME) program Open
Inflammation is a key factor in the pathogenesis of sarcopenia, a negative prognostic factor in cancer. Higher neutrophil-to-lymphocyte ratio (NLR) is significantly associated with poorer overall survival (OS) across multiple tumor types a…
View article: 107P Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP)
107P Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP) Open
The highest prevalence of MSI is observed in colorectal (CRC), endometrial, and gastric cancers. Lately, MSI has expanded its clinical utility as predictive biomarker to immunotherapy (IO). IHC and/or PCR are the gold standard methods for …
View article: HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies Open
Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10–20% of gastric cancers. The implementation of targeted therapy against …
View article: HER2-positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
HER2-positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies Open
Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10-20% of gastric cancers. The implementation of targeted therapy against …
View article: Data from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study
Data from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study Open
Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rat…
View article: Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study
Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study Open
Supplementary Appendix including all supplementary tables and figures
View article: Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study
Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study Open
Supplementary Appendix including all supplementary tables and figures
View article: Data from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study
Data from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study Open
Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rat…
View article: Figure S1 from High <i>FGFR1–4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Figure S1 from High <i>FGFR1–4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer Open
Supplementary Figure 1. FGFR1-4 DNA CN, mRNA levels and ROC curves analysis. A) Waterfall plot representing the best antitumor response of FGFRi in 24 patients from 8 different cancer types treated at VHIO. FGFR1/2 amplification status and…
View article: Figure S5 from High <i>FGFR1–4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Figure S5 from High <i>FGFR1–4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer Open
Supplementary Figure 5. Relative expression levels of lucitanib-specific RTK targets and ligands in PDX and patient tumors. A) mRNA expression levels of 2544 genes detected by HTG in Pt325 samples (Pre-tt versus On-tt). Highlighted are som…
View article: Figure S2 from Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Figure S2 from Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors Open
Supplementary Figure S2. Model-predicted and observed serum phosphate concentrations vs erdafitinib plasma concentrations (left panel: total erdafitinib concentrations; right panel: unbound erdafitinib concentrations). Continuous and dashe…
View article: Figure S4 from High <i>FGFR1–4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Figure S4 from High <i>FGFR1–4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer Open
Supplementary Figure 4. Impact of FGF ligand blockade in FGFRi treatment response. A) Analysis of mRNA expression levels of FGF ligands by HTG. FGFR1-4 and FGF3/4/19 CN and mRNA status are depicted in the box underneath. Gene expression le…
View article: Supplementary Table S2 from High <i>FGFR1–4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Supplementary Table S2 from High <i>FGFR1–4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer Open
Supplementary Table S2 HTG OBP panel raw data
View article: Data from Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Data from Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria Open
Purpose:Most hyperprogression disease (HPD) definitions are based on tumor growth rate (TGR). However, there is still no consensus on how to evaluate this phenomenon.Patients and Methods:We investigated two independent cohorts of patients …
View article: Figure S1-S5 and Table S1-S3 from Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Figure S1-S5 and Table S1-S3 from Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria Open
Figure S1. Flowchart of study selection process with ICIs treatment. Figure S2. Flowchart of study selection process with TAs treatment. Figure S3. Overall Survival comparing HPD with non-HPD in patients with progression disease as best re…
View article: Figure S2 from High <i>FGFR1–4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Figure S2 from High <i>FGFR1–4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer Open
Supplementary Figure 2. FGFR1-3 protein expression in BC PDXs models. A) Western blot (WB) analysis of FGFR1 and FGFR3 protein expression in PDX models; CAL120 cells were used as positive control for FGFR1 expression. B) Clinical evolution…
View article: Figure S1-S5 and Table S1-S3 from Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Figure S1-S5 and Table S1-S3 from Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria Open
Figure S1. Flowchart of study selection process with ICIs treatment. Figure S2. Flowchart of study selection process with TAs treatment. Figure S3. Overall Survival comparing HPD with non-HPD in patients with progression disease as best re…
View article: Data from A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Data from A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations Open
Purpose:To investigate tolerability, efficacy, and pharmacokinetics/pharmacodynamics of Debio 1347, a selective FGFR inhibitor.Patients and Methods:This was a first-in-human, multicenter, open-label study in patients with advanced solid tu…